The study involved 16 participants who were not dependent on drugs, having six sessions where they received different doses of atomoxetine (Strattera) and methylphenidate (Ritalin). A placebo was also tested. To ensure fairness, neither the participants nor the supervisors knew who received which drug at any session.

Throughout, their feelings, motor skills, and physical health were observed using several tests, assessing these factors both before and after the drugs were given at specific intervals.

This study aimed to explore the differences between atomoxetine and methylphenidate, particularly in terms of their subjective effects. Atomoxetine is highlighted as having a different impact, with no significant similarity to methylphenidate regarding feelings of pleasure. The findings provide important insights that can inform future research and treatment strategies in ADHD management.

Understanding these differences is essential, especially considering the concerns about abuse potential in ADHD treatments.

Methylphenidate, in a higher dose, appeared to increase feelings of stimulation among participants, resembling feelings associated with certain known stimulants. Meanwhile, atomoxetine at high doses was relatively unpleasant, causing some discomfort.

Both drugs raised heart rate and blood pressure, though atomoxetine notably affected diastolic and systolic pressures more variably. Neither drug showed significant impacts on motor skills compared to placebo.

From the study's results, atomoxetine doesn't create the same subjective experiences as methylphenidate. Its potential for misuse appears low when judged against methylphenidate's effects.

This might suggest atomoxetine is less likely to be used recreationally or lead to dependency compared to methylphenidate, impacting how these medications are considered for treatment in various settings.